VAXCELL-BIO THERAPEUTICSVAXCELL-BIO THERAPEUTICSVAXCELL-BIO THERAPEUTICS

VAXCELL-BIO THERAPEUTICS

No trades
See on Supercharts

323990 fundamentals

Key facts

Market capitalization
Founded
CEO
Website
About

Vaxcell-Bio Therapeutics engages in the development of anti-cancer immunotherapy. It operates through the following business divisions: Anticancer Immunotherapy Sector, Pet Healthcare Division, and Distribution Sector including Pharmaceuticals and Medical Supplies. The Anticancer Immunotherapy Sector business division develops an anticancer immunotherapy and is currently in the clinical trial/research stage. The Pet Healthcare business division refers to items from the Goldmun product group. The Distribution Sector including Pharmaceuticals and Medical Supplies business division consists of hunteraze, prolia freefield, innoen levofloxacin injection, albumin, and inoenseftriaxone. The company was founded by Lee Jae-Jung on February 18, 2010 and is headquartered in Hwasun-gun, South Korea.

Valuation

Fundamental metrics to determine fair value of the stock

Summary
No data available
There's currently no market capitalization, revenue or net income data to show.
Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

No dividends
323990 has never paid dividends and has no current plans to do so.

Financial health

Financial position and solvency of the company